Jeffrey L. Cummings – författare

As the global population ages the impact of neurodegenerative diseases like Alzheimer's disease and Parkinson's disease are significant forces in shaping human health and quality of life in the 21st century. Insights into understanding these diseases, and knowing how to treat them are major frontiers of scientific research.Neurodegenerative Diseases: Unifying Principles is the result of a conceptual revolution over the last decade in our understanding of neurodegenerative diseases as sharing unifying features. There is an increasing appreciation of the common biological and pathological features across seemingly varied neurodegenerative diseases that entail protein misfolding dysfunction and its consequences over time. Providing an overview of this conceptual change is the main theme for the book. Conventional approach emphasize the differences among neurodegenerative disorders, here Drs. Cummings and Pillai compile the increasingly compelling evidence that these disorders share many features and that insights in one may be rapidly translated into advances in another. The goal is to accelerate understanding by showing linkages among biological, pathological, can clinical aspects of this class of diseases.This collection of 19, inter-related chapters, articulates and broadens our view of the unifying features that initiate and drive disease progression across a variety of neurodegenerative diseases over time. This book will serve as an outstanding sourcebook of insights from experts that have played key roles in this story.

This is the long-awaited new edition of Jeffrey Cummings' classic work, Clinical Neuropsychiatry, originally published in 1985. That book represented an integration of behavioural neurology and biological psychiatry into a single volume devoted to explicating brain-behaviour relationships. It was clinically oriented and intended for practitioners caring for patients with neuropsychiatric disorders. The new title reflects the authors' effort to link the recent explosion of new information from neurochemistry, neuroanatomy, genetics, neuropharmacology, neuropathology, and neuroimaging to the clinical descriptions. Yet the clinical emphasis of its predecessor has been maintained. Each chapter has a consistent approach and the book as whole provides a practical, easy-to-use synthesis of clinical advice and basic science. The volume is enchanced by 4-colour images throughout. It is intended for students, residents, fellows, and practitioners of neurology, psychiatry, neuropsychology, and cognitive neuroscience. It will also be interest to individuals in neuroimaging.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Unique in approach and authority and illustrated with informative case histories, Behavior and Mood Disorders in Focal Brain Lesions, first published in 2000, makes a major contribution to understanding the relationship between focal brain disorders and emotional and behavioural symptoms, summarising the current state of research and providing the basis for improved patient care. This is the first clinical reference work to address specifically the relationship of focal brain dysfunction to behavioral and emotional disorders, giving the most comprehensive account available of these manifestations of brain lesions including stroke, trauma, epilepsy, multiple sclerosis, and even neurosurgery. A worldwide team of neuroscientists and clinicians examines the links between regional brain dysfunction and disorders of mood, thought and affect processing, and behaviour. Chapters are devoted to methodological issues, to lesions of specific sites, such as the frontal lobes, basal ganglia and thalamus, and to symptoms such as mood disorder, violent behaviour and anosognosia.

Growth in the incidence of dementia presents major challenges to global healthcare systems. As the burden of dementia in non-Western cultures grows, developing nations are expected to overtake developed nations in terms of dementia prevalence. Insights from developing nations and transcultural considerations are, nevertheless, neglected in the published literature. Dementia: A Global Approach fills this gap by integrating contemporary cross-cultural knowledge about dementia. Each section reviews the literature from the published, predominantly Western, perspective, contrasting it with empirical knowledge from non-Western cultures. Covering major clinical, epidemiological and scientific areas of interest, detailed consideration is also given to care-giving models across the world and management of patients who have migrated between regions. Enriched with personal insights from clinical experts across the globe, this is a key text for neurologists, geriatricians, psychiatrists, psychologists, epidemiologists and all those responsible for managing provisions of dementia services.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

This authoritative work, now thoroughly revised, has given thousands of clinicians, students, and researchers a state-of-the-art understanding of the human frontal lobes--the large brain region that plays a critical role in behavior, cognition, health, and disease. Leading experts from multiple disciplines address the anatomy and chemistry of the frontal cortex, neuropsychological assessments of capabilities unique to the frontal lobes, the nature of (and possible treatment avenues for) frontotemporal dementia and related conditions, and implications for understanding and treating neuropsychiatric disorders, such as schizophrenia, mania, and depression. Illustrations include eight pages in full color.New to This Edition:*Reflects a decade of important research advances in such areas as functional connectivity mapping of frontal and frontal-subcortical circuits.*Incorporates significant new information on frontotemporal dementia and other neurological disorders.*Expanded section on neuropsychiatric disorders, with new chapters on apathy, dissociative states, and antisocial behavior.*Chapters on salience networks, normal brain aging, white matter diseases, and clinical trials.*Increased attention to brain processes involved in moral reasoning, empathy, decision making, and other key human capabilities.

The third edition of the popular Textbook of Geriatric Neuropsychiatry thoroughly reviews this clinical subspecialty devoted to the diagnosis and treatment of psychiatric and behavior disorders in aging patients who display impaired brain function. In this text, world-renowned neuropsychiatrists and neuroscientists provide practical application of the latest research for both experienced clinicians and those new to the study of neuropsychiatry for the elderly. The book provides a comprehensive approach to treatment and contemporary neuroscience: Addresses the reality of an increasing aging population and the accompanying psychosocial changes this brings for patients and caregivers. Focuses on the health care of patients with neuropsychiatric illness. Consolidating the continued explosion of neuroscience research and the understanding of human behavior as it relates to aging. Bridges the fields of geriatric neurology and geriatric psychiatry, emphasizing relationships between neuropsychiatric illness and the aging of the nervous system. Responds to advancements in the study and science of geriatric neuropsychiatry, as well as feedback from past readers and clinicians. Concise and organized for easy reference, the textbook is divided into four parts that disclose clinically relevant information within the context of the very latest in neuroscience research and clinical application, including: Clinical definitions of the essential neuropsychiatric syndromes and disorders commonly seen in the elderly and how these disorders manifest. Emphasis on the principles and special considerations essential for the safe and effective treatment of neuropsychiatric disorders in the elderly. Study of the importance of interactions among aging; psychosocial, family, and neuropharmacological elements; and brain stimulation therapies. In-depth review of the influence of the aging nervous system on the pathophysiology, neuropsychiatric manifestations, clinical course, and prognosis of neurological and psychiatric illness in the elderly. Geriatric neuropsychiatry is an integrative specialty that draws from a diversity of fields including psychiatry, neuropsychiatry, neuroimaging, neuropsychopharmacology, gerontology, genetics, and molecular biology, to name a few. Incorporating these perspectives, this text is highly recommended for psychiatrists, neurologists, psychologists, geriatricians, psychiatric nurses, residents and fellows, and other clinicians interested in the study and treatment of the effects of aging on the brain.